Last reviewed · How we verify

GLP-1 analogue

Tanabe Pharma Corporation · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

GLP-1 analogue is a Small molecule drug developed by Tanabe Pharma Corporation. It is currently FDA-approved.

GLP-1 analogues are small molecule medications used to treat conditions such as Type 1 diabetes, hyperlipidemias, and obesity. They are administered as an intervention to help manage these conditions, although the exact mechanism of action is not specified in the provided facts.

At a glance

Generic nameGLP-1 analogue
SponsorTanabe Pharma Corporation
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GLP-1 analogue

What is GLP-1 analogue?

GLP-1 analogue is a Small molecule drug developed by Tanabe Pharma Corporation.

Who makes GLP-1 analogue?

GLP-1 analogue is developed and marketed by Tanabe Pharma Corporation (see full Tanabe Pharma Corporation pipeline at /company/tanabe-pharma-corporation).

What development phase is GLP-1 analogue in?

GLP-1 analogue is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing